Last edition
News about "satralizumab"
US FDA Approves Roche's Enspryng for Thyroid Eye Disease
The US FDA has approved Roche’s Enspryng, a first-in-class IL-6R inhibitor, as the first and only at-home subcutaneous treatment option for thyroid eye disease (TED).
Satralizumab | 17/10/2026 | By News Bureau
US FDA Grants Priority Review to Genentech?s Enspryng for MOGAD
The US Food and Drug Administration (FDA) has granted priority review to Genentech’s Enspryng for MOGAD after phase 3 METEOROID data showed a 68 percent reduction in relapse risk.
Satralizumab | 11/09/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy